December 21, 2022
On December 21, 2022, IsoPlexis, a life sciences company with platforms that provide insights into how multi-functional immune cells communicate and respond, and Berkeley Lights, a life sciences tools company, announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction. Under the terms of the agreement, IsoPlexis shareholders will receive 0.612 shares of Berkeley Lights stock for each IsoPlexis share they hold. Following the close of the transaction, Berkeley Lights shareholders will own approximately 75.2 percent of the combined company, and IsoPlexis shareholders will own approximately 24.8 percent of the combined company. The combined company will be named PhenomeX. Cravath is representing IsoPlexis in connection with the transaction.
The Cravath team is led by partner Richard Hall and includes associates Saagar Kaul, Alexander E. Greenberg and Glory P. James on M&A matters; partners William V. Fogg and Matthew G. Jones and associate Janice T.P. Martindale on capital markets matters; partners Eric W. Hilfers and Amanda Hines Gold and associate Brendon J. Rivard on executive compensation and benefits matters; partner Christopher K. Fargo, senior attorney Andrew Carlon and associate Sonia Katharani-Khan on tax matters; partner Sasha Rosenthal-Larrea and associate Carys J. Webb on intellectual property matters; partner Margaret T. Segall, practice area attorney Nicole M. Peles and associates Lila J.E. Nojima and Damian J. O’Sullivan on regulatory matters; partner Matthew Morreale on environmental matters; and practice area attorney Brian M. Budnick on real estate matters. Morgan S. Lucey also worked on M&A matters; Clayton Hackney also worked on tax matters; and Star S. Gulant also worked on real estate matters.
Deals & Cases
November 02, 2021
Cravath represented IsoPlexis Corporation in connection with its $125 million initial public offering of common stock. IsoPlexis Corporation is a life sciences company building solutions to accelerate the development of curative medicines and personalized therapeutics. The shares were listed on The Nasdaq Global Select Market. The transaction closed on October 12, 2021.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.